Hostname: page-component-7c8c6479df-hgkh8 Total loading time: 0 Render date: 2024-03-28T17:18:54.102Z Has data issue: false hasContentIssue false

Pharmacogenetics of weight gain and obesity following clozapine treatment

Published online by Cambridge University Press:  16 April 2020

O. Yevtushenko
Affiliation:
Division of Psychiatry and Neuroscience, Queen's University Belfast, Belfast, United Kingdom
C. Lafferty
Affiliation:
Division of Psychiatry and Neuroscience, Queen's University Belfast, Belfast, United Kingdom
V. Aziz
Affiliation:
St Tydfil's Hospital, Merthyr, United Kingdom
A. Tyson
Affiliation:
Gwent NHS Trust, Wales, United Kingdom
N. Jamil
Affiliation:
Gwent NHS Trust, Wales, United Kingdom
G.P. Reynolds
Affiliation:
Division of Psychiatry and Neuroscience, Queen's University Belfast, Belfast, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Weight gain is a major problem associated with long-term antipsychotic drug treatment. Clozapine is known to induce particularly profound weight gain. Although the mechanism of it is not clearly understood, the 5-HT2C receptor and leptin are implicated in its development. The present study examined the effects of 5-HT2C and leptin gene polymorphisms on weight change and obesity in the patients on clozapine.

107 patients (mean age 39.5±10.1 y.) meeting ICD-10 criteria for schizophrenia or schizoaffective disorder receiving clozapine took part in this study. The patient assessment included an interview, measures of weight, height, waist-hip ratio, waist circumference, body mass index (BMI, kg/m2); blood samples were taken for random blood glucose and genetic testing for 5-HT2C and leptin gene.

Central obesity was present in 102 patients as defined by increased waist circumference and obesity in 67 patients as defined by BMI>30. Type II diabetes was present in 8 patients and type I diabetes in one. In 93 patients (62M, 31F) we assessed change in BMI and weight during treatment which was 2.6±4.2kg/m2 and 7.43±12.35 kg, respectively.

There was no association between 759C/T 5-HT2C receptor and -2548A/G leptin gene polymorphisms with BMI or weight.

No association between 759C/T 5-HT2C receptor and -2548A/G leptin gene polymorphisms was found with change of BMI or waist circumference.

We found no significant association between 759C/T 5-HT2C receptor and -2548A/G leptin gene polymorphisms and changes in BMI or weight in the patients treated with clozapine.

Type
Poster Session 2: Biological Markers And Brain Imaging
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.